SCHEMBL7064948

SCHEMBL7064948

Cc1ccc(-c2ccccc2)cc1NC(=O)Nc1ccc(-c2ccc(N3CCOCC3)nc2C)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
MCL1 Q07820 2/20 0.42
KDR P35968 1/20 0.42
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 3/20 0.41
CLK2 P49760 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CSNK2A1 P68400 1/20 0.41
STK3 Q13188 1/20 0.41
HIPK4 Q8NE63 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464429 0.86 PIK3CA (0.52) KDM4EMEN1USP2KMT2AALDH1A1
SCHEMBL7070212 0.79 MAPK14 (0.49) KDM4EMEN1USP2KMT2AALDH1A1
SCHEMBL7067699 0.79 CNR1 (0.47) KDM4EMEN1USP2KMT2AALDH1A1
SCHEMBL7189256 0.78 RAF1 (0.54) KDM4EGAACLK2GSK3AGSK3B
SCHEMBL4088174 0.77 MAPK14 (0.65) MCL1MAPK14AKT1
SCHEMBL4456006 0.77 MAPK1 (0.42) KDM4EMEN1USP2KMT2AALDH1A1
SCHEMBL28747223 0.77 CLK2 (0.49) KDM4EMEN1USP2KMT2AHPGD
SCHEMBL7069390 0.77 EPHX2 (0.49) KDM4EALDH1A1GAACLK2GSK3A
SCHEMBL27559838 0.76 MAPK14 (0.54) KDM4EKMT2AALDH1A1HPGDLMNA
SCHEMBL7069581 0.76 BRAF (0.53) GSK3AMAPK14AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220336-A1 Method of treating mucus hypersecretion BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220336-A1 Method of treating mucus hypersecretion MUC1, CFTR, MAPKAPK5 KDM4E 4714/4885MEN1 4080/4885USP2 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.